CTLA-4: From mechanism to autoimmune therapy
- PMID:32007707
- DOI: 10.1016/j.intimp.2020.106221
CTLA-4: From mechanism to autoimmune therapy
Abstract
CD28 and CTLA-4 are both important stimulatory receptors for the regulation of T cell activation. Because receptors share common ligands, B7.1 and B7.2, the expression and biological function of CTLA-4 is important for the negative regulation of T cell responses. Therefore, elimination of CTLA-4 can result in the breakdown of immune tolerance and the development of several diseases such as autoimmunity. Inhibitory signals of CTLA-4 suppress T cell responses and protect against autoimmune diseases in many ways. In this review, we summarize the structure, expression and signaling pathway of CTLA-4. We also highlight how CTLA-4 defends against potentially self-reactive T cells. Finally, we discuss how the CTLA-4 regulates a number of autoimmune diseases that indicate manipulation of this inhibitory molecule is a promise as a strategy for the immunotherapy of autoimmune diseases.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
- Mechanisms of CTLA-4-Ig in tolerance induction.Alegre ML, Fallarino F.Alegre ML, et al.Curr Pharm Des. 2006;12(2):149-60. doi: 10.2174/138161206775193046.Curr Pharm Des. 2006.PMID:16454732Review.
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.Fife BT, Bluestone JA.Fife BT, et al.Immunol Rev. 2008 Aug;224:166-82. doi: 10.1111/j.1600-065X.2008.00662.x.Immunol Rev. 2008.PMID:18759926Review.
- CTLA-4 and T cell activation.Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB, Sharpe AH.Oosterwegel MA, et al.Curr Opin Immunol. 1999 Jun;11(3):294-300. doi: 10.1016/s0952-7915(99)80047-8.Curr Opin Immunol. 1999.PMID:10375557Review.
- The CD28-B7 costimulatory pathway and its role in autoimmune disease.Daikh D, Wofsy D, Imboden JB.Daikh D, et al.J Leukoc Biol. 1997 Aug;62(2):156-62. doi: 10.1002/jlb.62.2.156.J Leukoc Biol. 1997.PMID:9261329Review.
- B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.Linsley PS, Greenbaum CJ, Speake C, Long SA, Dufort MJ.Linsley PS, et al.JCI Insight. 2019 Feb 21;4(4):e126136. doi: 10.1172/jci.insight.126136. eCollection 2019 Feb 21.JCI Insight. 2019.PMID:30830871Free PMC article.
Cited by
- Present and Future of Immunotherapy for Triple-Negative Breast Cancer.Sriramulu S, Thoidingjam S, Speers C, Nyati S.Sriramulu S, et al.Cancers (Basel). 2024 Sep 24;16(19):3250. doi: 10.3390/cancers16193250.Cancers (Basel). 2024.PMID:39409871Free PMC article.Review.
- Noninvasive radiomic analysis of enhanced CT predicts CTLA4 expression and prognosis in head and neck squamous cell carcinoma.Zhu Y, Wu M.Zhu Y, et al.Sci Rep. 2023 Oct 5;13(1):16782. doi: 10.1038/s41598-023-43582-0.Sci Rep. 2023.PMID:37798374Free PMC article.
- Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review.Jamee M, Hosseinzadeh S, Sharifinejad N, Zaki-Dizaji M, Matloubi M, Hasani M, Baris S, Alsabbagh M, Lo B, Azizi G.Jamee M, et al.Clin Exp Immunol. 2021 Jul;205(1):28-43. doi: 10.1111/cei.13600. Epub 2021 May 3.Clin Exp Immunol. 2021.PMID:33788257Free PMC article.Review.
- A Narrative Review of Current Knowledge on Cutaneous Melanoma.Caraban BM, Aschie M, Deacu M, Cozaru GC, Pundiche MB, Orasanu CI, Voda RI.Caraban BM, et al.Clin Pract. 2024 Jan 26;14(1):214-241. doi: 10.3390/clinpract14010018.Clin Pract. 2024.PMID:38391404Free PMC article.Review.
- Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer.Zhang X, Cai X, Yan C.Zhang X, et al.J Cancer Res Clin Oncol. 2023 Dec;149(20):18253-18270. doi: 10.1007/s00432-023-05499-z. Epub 2023 Nov 20.J Cancer Res Clin Oncol. 2023.PMID:37985502Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical